Beacon Pharmaceuticals PLC (DSE: BEACONPHAR)

Market Cap	30.68B
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	231.00M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	2.00 (1.51%)
Ex-Dividend Date	Oct 28, 2024

Volume	177,977
Open	135.50
Previous Close	135.50
Day's Range	131.00 - 138.00
52-Week Range	104.80 - 288.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, chronic care, and biotech products. It also provides various therapeutic products that include anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, anti-histamine, analgesics, and NSAIDS, as...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 3,872
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2023, Beacon Pharmaceuticals's revenue was 8.51 billion, an increase of 6.07% compared to the previous year's 8.02 billion. Earnings were 509.84 million, a decrease of -45.47%.